Overview

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Status:
Completed
Trial end date:
2017-08-17
Target enrollment:
Participant gender:
Summary
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals